Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Public health advisory for Trasylol issued by U.S. FDA
March 24th, 2006
The U.S. Food & Drug Administration (FDA) has issued a public health advisory alerting doctors who perform heart bypass surgery, and their patients, that Trasyolol (aprotinin injection), a drug used to prevent blood loss during surgery, has been linked in two scientific publications to higher risks of serious side effects including kidney problems, heart attacks, and strokes in patients who undergo artery bypass graft surgery. "FDA is conducting a thorough evaluation of the safety profile for this drug in light of the recent publications," said Dr. Steven Galson, director of FDA's Center for Drug Evaluation and Research. "We're working to evaluate the potential risks...
Source: Drug Week (2006-03-24)
|
